Product Overview

Diabetrol SR is a sustained‑release oral antidiabetic medication formulated by Abbott India Pvt. Ltd. It combines two well‑established hypoglycemic agents, glibenclamide (5 mg) and metformin (500 mg), in a single tablet designed to improve glycemic control in adults with type 2 diabetes mellitus. The sustained‑release (SR) formulation allows for a more stable plasma concentration over an extended period, reducing the frequency of dosing and supporting better adherence. Each strip contains ten tablets, and the product is marketed in pack sizes of 60, 90, and 120 tablets, with delivery typically occurring within 6 to 15 days.

What is Diabetrol SR (Glibenclamide Metformin)

Diabetrol SR belongs to the class of oral hypoglycemics that work through complementary mechanisms. Glibenclamide, a second‑generation sulfonylurea, stimulates pancreatic beta‑cells to release insulin, thereby lowering fasting and post‑prandial glucose levels. Metformin, a biguanide, decreases hepatic glucose production, improves peripheral insulin sensitivity, and modestly enhances peripheral glucose uptake. The combination provides a synergistic effect that addresses both insulin deficiency and insulin resistance, two major pathophysiological contributors to type 2 diabetes. The medication is indicated for patients who have not achieved adequate glycemic control with monotherapy or who require additional therapy to meet target HbA1c goals.

Uses and Benefits

The primary use of Diabetrol SR is the pharmacologic management of type 2 diabetes when diet, exercise, and weight control alone are insufficient. Clinical studies have demonstrated that the SR formulation offers several patient‑centric benefits:

• Improved glycemic control with a reduced risk of nocturnal hypoglycemia compared with immediate‑release sulfonylureas.
• Maintenance of stable blood glucose levels over 24 hours, facilitating once‑daily dosing.
• Potential weight neutrality or modest weight loss, which is advantageous for many individuals with type 2 diabetes.
• Convenient dosing schedule that supports medication adherence, a critical factor in long‑term disease management.

By maintaining target glucose concentrations, patients may experience a lower incidence of diabetes‑related complications such as cardiovascular events, nephropathy, and retinopathy. The product’s sustained‑release design also minimizes peaks and troughs in plasma drug levels, contributing to a smoother therapeutic profile.

How It Works

The pharmacodynamic interaction of glibenclamide and metformin in Diabetrol SR creates a dual‑action mechanism. After oral administration, glibenclamide is rapidly absorbed in the gastrointestinal tract, crossing the intestinal mucosa and binding to the sulfonylurea receptor (SUR1) on pancreatic beta‑cells. This binding triggers closure of ATP‑sensitive potassium channels, leading to depolarization and subsequent insulin secretion. Simultaneously, metformin is absorbed more slowly due to the SR matrix, delivering a controlled release of the drug into the systemic circulation. Metformin inhibits hepatic gluconeogenesis by down‑regulating key enzymes (e.g., phosphoenolpyruvate carboxykinase) and enhances peripheral glucose utilization through activation of AMP‑activated protein kinase (AMPK). The combined effect results in a comprehensive reduction of both fasting and post‑prandial hyperglycemia, supporting sustained glycemic control.

Dosage Guidelines

Dosage of Diabetrol SR must be individualized based on the patient’s current glycemic status, renal function, and concomitant antidiabetic therapy. The typical starting dose for adults is one tablet (5 mg glibenclamide/500 mg metformin) taken once daily with the morning meal. If additional glycemic control is required, the dose may be titrated upward in increments of one tablet at intervals of 1–2 weeks, not exceeding a maximum of six tablets per day (30 mg glibenclamide/3000 mg metformin). Patients with impaired renal function (estimated glomerular filtration rate < 45 mL/min/1.73 m²) should avoid use or require dose reduction, as metformin accumulation can increase the risk of lactic acidosis. It is essential that patients undergo periodic renal function assessment and that dose adjustments are made in accordance with clinical guidelines. Missed doses should be taken as soon as remembered unless it is nearly time for the next scheduled dose; doubling the dose is not recommended.

Side Effects

Like all pharmacologic agents, Diabetrol SR may be associated with adverse effects. The most frequently reported side effects include:

• Hypoglycemia, particularly when used in combination with other glucose‑lowering agents or in patients with irregular eating patterns.
• Gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal discomfort, and decreased appetite.
• Weight gain, although less common than with some other sulfonylureas.
• Rare but serious adverse events including hepatic enzyme elevations, pancreatitis, and lactic acidosis.

Patients should be instructed to monitor for symptoms of hypoglycemia (e.g., sweating, tremors, confusion) and to treat promptly with glucose if necessary. If gastrointestinal symptoms persist or become severe, medical evaluation is advised. Any signs of hepatic dysfunction (e.g., dark urine, jaundice) or unexplained muscle pain should prompt immediate discontinuation of the medication and consultation with a healthcare professional.

Warnings and Precautions

Several precautions are recommended before initiating Diabetrol SR therapy:

• Renal impairment: Metformin is contraindicated in patients with an estimated GFR < 30 mL/min/1.73 m² and should be used cautiously in those with GFR 30‑45 mL/min/1.73 m².
• Hypersensitivity: Patients with a known hypersensitivity to glibenclamide, metformin, or any component of the formulation should avoid use.
• Pregnancy and lactation: The safety of Diabetrol SR during pregnancy and breastfeeding has not been established; alternative therapies are generally preferred.
• Surgery or procedures requiring contrast: Metformin should be temporarily discontinued prior to imaging studies involving intravascular contrast to reduce the risk of contrast‑induced nephropathy.
• Alcohol consumption: Excessive alcohol intake can potentiate the risk of lactic acidosis.

It is advisable for patients to undergo regular monitoring of blood glucose, renal function, and liver enzymes throughout the course of therapy. Education regarding proper diet and exercise remains a cornerstone of diabetes management, and pharmacologic therapy should complement, not replace, these lifestyle measures.

Frequently Asked Questions

1. Can Diabetrol SR be taken by patients with type 1 diabetes?
Diabetrol SR is specifically indicated for type 2 diabetes. It is not approved for use in patients with type 1 diabetes or in those who require insulin therapy.

2. How long does it take to see a reduction in HbA1c levels?
Clinical trials have shown that a measurable decrease in HbA1c can be observed within 4–6 weeks of consistent daily use, although individual response may vary based on baseline glycemic control and adherence.

3. Is it safe to combine Diabetrol SR with other antidiabetic medications?
Combining Diabetrol SR with other glucose‑lowering agents, such as SGLT2 inhibitors or other sulfonylureas, may increase the risk of hypoglycemia. Any combination therapy should be initiated under the supervision of a qualified healthcare professional.

4. What should I do if I miss a dose?
If a dose is missed, it should be taken as soon as remembered unless it is close to the time for the next scheduled dose. In the latter case, the missed dose should be skipped, and the regular dosing schedule resumed; doubling the dose is not recommended.

5. Are there any dietary restrictions while on Diabetrol SR?
Patients are encouraged to follow a balanced, carbohydrate‑controlled diet and to maintain regular physical activity. Alcohol intake should be moderate, and patients should avoid excessive consumption that could increase the risk of hypoglycemia or lactic acidosis.

For additional information on diabetes management and medication safety, reputable sources such as the National Institutes of Health, the U.S. Food and Drug Administration, and MedlinePlus provide evidence‑based guidance.

Related Products

• Faceclin Gel (Clindamycin/Nicotinamide)
• Okamet 500 Mg (Metformin)
• Resteclin 500 mg (Tetracycline)
• Erythrocin 250 mg (Erythromycin)
• Flagyl 200mg (Metronidazole)
• Flagyl 400mg (Metronidazole)
• Flagyl (Metronidazole)
• Tetracycline 500 mg (Generic)
• Tetracycline 250 mg (Generic)
• Resteclin (Tetracycline)
• Resteclin 250 mg (Tetracycline)
• Erythrocin (Erythromycin)